Endo International PLC (NASDAQ:ENDP) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

Several other equities research analysts also recently weighed in on ENDP. Vetr raised Endo International PLC from a “hold” rating to a “buy” rating and set a $11.34 price objective for the company in a report on Tuesday, May 9th. Canaccord Genuity set a $14.00 price objective on Endo International PLC and gave the company a “hold” rating in a report on Thursday, May 11th. BMO Capital Markets reissued a “hold” rating and issued a $16.00 price objective on shares of Endo International PLC in a report on Wednesday, May 17th. Mizuho reissued a “buy” rating and issued a $19.00 price objective (up from $18.00) on shares of Endo International PLC in a report on Thursday, May 25th. Finally, Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Endo International PLC in a report on Thursday, June 8th. Three investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $14.75.

Shares of Endo International PLC (NASDAQ:ENDP) traded down 1.71% during mid-day trading on Friday, reaching $8.64. 3,142,559 shares of the company’s stock traded hands. The firm’s market cap is $1.93 billion. Endo International PLC has a one year low of $7.41 and a one year high of $23.98. The firm’s 50-day moving average is $9.73 and its 200 day moving average is $11.17.

Endo International PLC (NASDAQ:ENDP) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. The business had revenue of $875.73 million during the quarter, compared to the consensus estimate of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The company’s revenue was down 4.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.86 earnings per share. Analysts predict that Endo International PLC will post $3.51 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/03/valuengine-downgrades-endo-international-plc-endp-to-hold.html.

In other news, CEO Paul Campanelli purchased 6,500 shares of the company’s stock in a transaction dated Monday, August 14th. The stock was acquired at an average price of $7.71 per share, for a total transaction of $50,115.00. Following the completion of the transaction, the chief executive officer now directly owns 213,620 shares in the company, valued at approximately $1,647,010.20. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Terrance J. Coughlin purchased 20,000 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was purchased at an average price of $7.70 per share, with a total value of $154,000.00. Following the transaction, the chief operating officer now owns 181,369 shares of the company’s stock, valued at $1,396,541.30. The disclosure for this purchase can be found here. In the last three months, insiders acquired 36,000 shares of company stock valued at $279,460. 0.50% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. OppenheimerFunds Inc. increased its position in shares of Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after buying an additional 1,857,678 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares in the last quarter. Diamond Hill Capital Management Inc. purchased a new position in shares of Endo International PLC in the second quarter valued at $5,454,000. Ameriprise Financial Inc. increased its position in shares of Endo International PLC by 685.0% in the first quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock valued at $6,185,000 after buying an additional 483,545 shares in the last quarter. Finally, American International Group Inc. increased its position in shares of Endo International PLC by 451.5% in the first quarter. American International Group Inc. now owns 396,887 shares of the company’s stock valued at $4,429,000 after buying an additional 324,922 shares in the last quarter. Institutional investors and hedge funds own 90.74% of the company’s stock.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.